Definium Therapeutics News - June 22, 2026
🟢 DFTX surges 49.8% today on positive Phase 3 results, then drops in after-hours on $500M equity offering
DFTX surged 49.80% to close at $36.67 today after reporting positive topline results from its Phase 3 Emerge study of DT120 ODT in Major Depressive Disorder. •...
Definium Therapeutics plans $500 million share sale following stock rally
Definium Therapeutics announced a proposed $500 million public offering of common shares and pre-funded warrants on June 22, 2026. The biopharmaceutical...
Definium's Depression Drug Clears a Key Hurdle, but Can a Single-Dose LSD Therapy Justify a $4 Billion Valuation?
Shares of Definium Therapeutics surged +52.6% to $37.35 after the company reported that its lead psychedelic-based treatment — a single-dose, orally dissolving...
🟢 Definium Therapeutics, Inc. is trading 52.6% up today after positive Phase 3 Emerge results for DT120 ODT
Definium Therapeutics, Inc. is trading at $37.35 (+52.57%) after announcing positive topline Phase 3 Emerge results for DT120 ODT in major depressive...
Reports Positive Phase 3 Emerge Study Data for Depression Treatment DT120 ODT
Definium Therapeutics announced positive topline results from its Phase 3 Emerge study for DT120 ODT (lysergide), a treatment for adults with major depressive...
🟢 Definium Therapeutics, Inc. trading 13.4% up as company discusses Phase 3 Emerge study results today
Definium Therapeutics, Inc. is trading 13.4% up at $27.75 in pre-market. The company is discussing topline results from its Phase 3 Emerge study in Major...